Yoichiro Hirakawa1, Hisatomi Arima, Ruth Webster, Sophia Zoungas, Qiang Li, Stephen Harrap, Liu Lisheng, Pavel Hamet, Giuseppe Mancia, Neil Poulter, Bruce Neal, Bryan Williams, Anthony Rogers, Mark Woodward, John Chalmers. 1. aThe George Institute for Global Health, University of Sydney, SydneybSchool of Public Health, Monash UniversitycUniversity of Melbourne, Royal Melbourne Hospital, Melbourne, AustraliadChinese Hypertension League Institute, Beijing, ChinaeResearch Centre, Centre hospitalier del'Université de Montréal, Montreal, CanadafIstituto Auxologico Italiano, University of Milan-Bicocca, Milan, ItalygInternational Centre for Circulatory Health, Imperial CollegehUniversity College London (UCL) and the National Institute for Health Research UCL Hospitals Biomedical Research Centre, LondoniNuffield Department of Population Health, The George Institute for Global Health, University of Oxford, Oxford, UK.
Abstract
OBJECTIVE: The associations of discontinuation of the study medication on major outcomes were assessed in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Trial. METHODS: ADVANCE was a factorial randomized controlled trial of blood pressure lowering (a fixed combination of perindopril and indapamide vs. placebo) and intensive glucose control (vs. standard glucose control) in patients with type 2 diabetes. Patients who permanently discontinued the randomized blood pressure-lowering medication during the study period (n = 1557) were compared with others (n = 9583). Cox's proportional hazards models were used to estimate the effects of the discontinuation on the risks of macrovascular events, microvascular events together and separately and all-cause mortality, using discontinuation as a time-dependent covariate. RESULTS: In multivariable analyses, discontinuation was associated with increased risks of combined macro and microvascular events (hazard ratio 2.24, 95% CI 1.96-2.57), macrovascular events (3.23, 2.75-3.79), microvascular events (1.38, 1.11-1.71), and all-cause mortality (7.99, 6.92-9.21) compared to continuing administration of randomized medications during the trial period, which were highest in the first year after discontinuation. These associations were similar in active and placebo groups, except in the first year after discontinuation during which event rates were lower in the active group than in the placebo group (P ≤ 0.01). CONCLUSION: Discontinuation of study medication is a potent risk marker for identifying high-risk patients. Thus it is important that clinicians seek to identify such patients early after discontinuation of treatment. Although some short-term residual effects of previous active treatment can be expected, patients who discontinue require further urgent investigation and management.
RCT Entities:
OBJECTIVE: The associations of discontinuation of the study medication on major outcomes were assessed in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Trial. METHODS: ADVANCE was a factorial randomized controlled trial of blood pressure lowering (a fixed combination of perindopril and indapamide vs. placebo) and intensive glucose control (vs. standard glucose control) in patients with type 2 diabetes. Patients who permanently discontinued the randomized blood pressure-lowering medication during the study period (n = 1557) were compared with others (n = 9583). Cox's proportional hazards models were used to estimate the effects of the discontinuation on the risks of macrovascular events, microvascular events together and separately and all-cause mortality, using discontinuation as a time-dependent covariate. RESULTS: In multivariable analyses, discontinuation was associated with increased risks of combined macro and microvascular events (hazard ratio 2.24, 95% CI 1.96-2.57), macrovascular events (3.23, 2.75-3.79), microvascular events (1.38, 1.11-1.71), and all-cause mortality (7.99, 6.92-9.21) compared to continuing administration of randomized medications during the trial period, which were highest in the first year after discontinuation. These associations were similar in active and placebo groups, except in the first year after discontinuation during which event rates were lower in the active group than in the placebo group (P ≤ 0.01). CONCLUSION: Discontinuation of study medication is a potent risk marker for identifying high-risk patients. Thus it is important that clinicians seek to identify such patients early after discontinuation of treatment. Although some short-term residual effects of previous active treatment can be expected, patients who discontinue require further urgent investigation and management.
Authors: F Fici; G Seravalle; N Koylan; I Nalbantgil; N Cagla; Y Korkut; F Quarti-Trevano; W Makel; G Grassi Journal: High Blood Press Cardiovasc Prev Date: 2017-05-11
Authors: Giuseppe Mancia; Federico Rea; Monica Ludergnani; Giovanni Apolone; Giovanni Corrao Journal: N Engl J Med Date: 2020-05-01 Impact factor: 91.245
Authors: Sonali R Gnanenthiran; Claudio Borghi; Dylan Burger; Bruno Caramelli; Fadi Charchar; Julio A Chirinos; Jordana B Cohen; Antoine Cremer; Gian Luca Di Tanna; Alexandre Duvignaud; Daniel Freilich; D H Frank Gommans; Abraham E Gracia-Ramos; Thomas A Murray; Facundo Pelorosso; Neil R Poulter; Michael A Puskarich; Konstantinos D Rizas; Rodolfo Rothlin; Markus P Schlaich; Michael Schreinlecher; Ulrike Muscha Steckelings; Abhinav Sharma; George S Stergiou; Christopher J Tignanelli; Maciej Tomaszewski; Thomas Unger; Roland R J van Kimmenade; Richard D Wainford; Bryan Williams; Anthony Rodgers; Aletta E Schutte Journal: J Am Heart Assoc Date: 2022-08-24 Impact factor: 6.106
Authors: David Wong; Stephen Gerry; Farah Shamout; David A Clifton; Marco A F Pimentel; Peter J Watkinson Journal: BMJ Open Date: 2020-05-05 Impact factor: 2.692